Nov 14, 2019
EMulate® Therapeutics Announces Multiple Presentations on the Voyager and Hælo® systems
Sep 13, 2019
Kazia wins ANZLF Trans-Tasman Innovation & Growth Award and reports new data from clinical trial in childhood brain cancer
Sep 12, 2019
St Jude Study of GDC-0084 in DIPG Successfully Completes First Stage; Second Part of Study Now Underway
Aug 28, 2019
EMulate Therapeutics® Submits Application for CE Mark
Jul 09, 2019
EMulate Therapeutics® Reaches Patent Milestone
May 01, 2019
Real-Time May Day on Capitol Hill: DIPG Advocacy Group's Relentless Fight for Children with Brain Cancer In a Culture of Indifference
Mar 12, 2019
xCures to Implement an Intermediate Size Expanded Access Protocol for ONC201 in H3 K27M-mutant Gliomas
Jan 03, 2019
Tragara Pharmaceuticals Appoints Scott Megaffin as Chief Executive Officer and Changes Name to Adastra Pharmaceuticals
Dec 04, 2018
A Moonshot for Kids: DIPG Awareness Resolution H.Res.69 Runs out of Time as Childhood Cancer Advocates Return to Capitol Hill
Jul 25, 2018
Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent TP-0184, an Activin A Receptor Type 1 (ACVR1) Inhibitor, in Phase 1 Study of Patients with Advanced Solid Tumors
May 08, 2018
Successful Delivery of DNAtrix's Oncolytic Virus DNX-2401 to Pediatric Brain Tumors
Dec 07, 2017
Alcyone Lifesciences Announces First Pediatric Patient Treated with AMC for Treatment of DIPG
Dec 05, 2017
DNAtrix Announces First Pediatric Patient Treated with Oncolytic Virus DNX-2401
Aug 15, 2017
Children's National part of pediatric cancer research collective awarded millions by NIH
May 26, 2017
First of Its Kind Clinical Trial for Children With DIPG to Make Data Available in the Cloud